# Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study

> **NCT06714370** · — · NOT_YET_RECRUITING · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 35 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma (PCNSL)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06714370
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06714370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06714370, "Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06714370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*